Most Popular

Sarepta (SRPT): Did You Feel the Ground Shake, Too?

Can you feel the ground moving beneath your feet? Shares of Sarepta (NASDAQ:SRPT) skyrocketed nearly 60% this morning, following the announcement of positive …

This Top Analyst Stands Behind Micron (MU) Ahead Of Tomorrow’s Print

RBC Capital analyst Amit Daryanani is one of Micron’s (NASDAQ:MU) biggest bulls, and he is also one of the top analysts rated who cover …

DPW Holdings (DPW) Uses Bitcoin to Reduce Debt; Shares Soar

DPW Holdings’ (NYSE:DPW) long-suffering bulls finally have a reason to cheer: The company announced today that it has used Bitcoin, the cryptocurrency its …

Former Helios and Matheson Analytics (HMNY) Bull Clears Right Out of Stock

Seeking Alpha’s Ben Rabizadeh has sold off all his remaining HMNY shares on his once “big speculative play.”

Top Analyst Shares Key Takeaways on Tesla (TSLA) Following 2nd Annual Needham Auto Tech Day

Needham’s Rajvindra Gill believes that once Tesla’s Model 3 achieves its targets, the leverage at play is meaningful.

Quant Genius Jim Simons Jumps into Micron (MU), Turns the Gas Up on Tesla (TSLA)

Here’s a glimpse into how one of Wall Street’s most successful hedge fund gurus chose to bet on Micron and Tesla in Q1.

DPW Holdings (DPW): Shoring Up the Balance Sheet by Selling Stock Comes with a Price

After pricing an equity offering that will dilute current investors but help shore up its balance sheet, shares in DPW Holdings Inc (NYSE:DPW) …

vTv Therapeutics (VTVT) Stock: Healthcare Analysts Move to the Sidelines

Last week, vTv Therapeutics Inc (NASDAQ:VTVT) announced that azeliragon, the company’s RAGE inhibitor in development for Alzheimer’s disease (AD) failed in Part A …

Tesla (TSLA) Still a ‘Show Me’ Story (In a Bad Way), Twitter (TWTR) Stock Wins an Upgrade

What does the future hold for Tesla (NASDAQ:TSLA) and Twitter (NYSE:TWTR)? Sell-side analysts from Bernstein and Morgan Stanley weigh in on the two tech giants, …

Bristol Myers Squibb (BMY) Will Face Significant Headwinds in 2019; Here’s Why

Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small cell lung cancer (NSCLC). The data was positive …